ECSP088714A - Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-lh- bencimidazol-5-il}etanosulfonamida - Google Patents

Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-lh- bencimidazol-5-il}etanosulfonamida

Info

Publication number
ECSP088714A
ECSP088714A EC2008008714A ECSP088714A ECSP088714A EC SP088714 A ECSP088714 A EC SP088714A EC 2008008714 A EC2008008714 A EC 2008008714A EC SP088714 A ECSP088714 A EC SP088714A EC SP088714 A ECSP088714 A EC SP088714A
Authority
EC
Ecuador
Prior art keywords
salt
acid
tert
methyl
etanosulfonamide
Prior art date
Application number
EC2008008714A
Other languages
English (en)
Inventor
Martin Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088714A publication Critical patent/ECSP088714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una sal del compuesto N-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-lH-bencimidazol-5-il}etanosulfonamida, la cual es una sal de ácido etanosulfónico, una sal de ácido sulfúrico, una sal de ácido etano disulfónico, una sal de ácido clorhídrico, una sal de ácido bromhídrico, una sal de ácido fosfórico, una sal de ácido acético, una sal de ácido fumárico, una sal de ácido maleico, una sal de ácido tartárico, una sal de ácido cítrico, una sal de ácido metanosulfónico, o una sal de ácido p-toluenosulfónico de dicho compuesto.
EC2008008714A 2006-03-23 2008-09-03 Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-lh- bencimidazol-5-il}etanosulfonamida ECSP088714A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78532606P 2006-03-23 2006-03-23

Publications (1)

Publication Number Publication Date
ECSP088714A true ECSP088714A (es) 2008-10-31

Family

ID=38522716

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008714A ECSP088714A (es) 2006-03-23 2008-09-03 Formas cristalinas de sales de n-{2-tert-butil-1-[(4,4-difluorociclohexil)metil]-lh- bencimidazol-5-il}etanosulfonamida

Country Status (18)

Country Link
US (2) US7566788B2 (es)
EP (1) EP2001856A4 (es)
JP (1) JP2009530373A (es)
KR (1) KR20080105098A (es)
CN (1) CN101454293A (es)
AR (1) AR060065A1 (es)
AU (1) AU2007227811A1 (es)
BR (1) BRPI0709631A2 (es)
CA (1) CA2648829A1 (es)
EC (1) ECSP088714A (es)
IL (1) IL193671A0 (es)
MX (1) MX2008012015A (es)
NO (1) NO20084353L (es)
RU (1) RU2008136556A (es)
TW (1) TW200745049A (es)
UY (1) UY30232A1 (es)
WO (1) WO2007108754A1 (es)
ZA (1) ZA200807598B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CN101758337B (zh) 2009-12-03 2012-02-15 湖南阿斯达生化科技有限公司 一种助焊剂用非卤素活性剂
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (es) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) * 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
EP0882718B1 (en) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
US6844367B1 (en) * 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) * 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
IL150150A0 (en) 2000-01-14 2002-12-01 Schering Ag 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation
US7115645B2 (en) * 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2004515496A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20050026968A1 (en) 2003-07-14 2005-02-03 University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
PT1773768T (pt) 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
US20060052421A1 (en) * 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
JP2008514592A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それらを含有する組成物、それらの製造及びそれらの使用iii
EP1797075A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands
BRPI0515897A (pt) * 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
EP1797074A4 (en) 2004-09-24 2009-04-01 Astrazeneca Ab COMPOUNDS, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND APPLICATIONS THEREOF IIII
EP1797070A1 (en) 2004-09-24 2007-06-20 AstraZeneca AB Compounds, compositions containing them, preparations thereof and uses thereof ii
JP2008514590A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
WO2006033631A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514594A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用i
CA2586179C (en) * 2004-11-02 2011-02-08 Pfizer Inc. Sulfonyl benzimidazole derivatives
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof

Also Published As

Publication number Publication date
ZA200807598B (en) 2010-02-24
KR20080105098A (ko) 2008-12-03
US20100022610A1 (en) 2010-01-28
EP2001856A4 (en) 2011-02-16
US20070225346A1 (en) 2007-09-27
UY30232A1 (es) 2007-10-31
JP2009530373A (ja) 2009-08-27
TW200745049A (en) 2007-12-16
WO2007108754A1 (en) 2007-09-27
CN101454293A (zh) 2009-06-10
MX2008012015A (es) 2008-10-01
EP2001856A1 (en) 2008-12-17
BRPI0709631A2 (pt) 2011-07-19
US7566788B2 (en) 2009-07-28
RU2008136556A (ru) 2010-04-27
IL193671A0 (en) 2009-05-04
CA2648829A1 (en) 2007-09-27
AU2007227811A1 (en) 2007-09-27
AR060065A1 (es) 2008-05-21
NO20084353L (no) 2008-10-16

Similar Documents

Publication Publication Date Title
DOP2012000149A (es) Compuestos triciclicos novedosos
AR090357A1 (es) Sales de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico
CL2016000405A1 (es) Uso de bardoxolón metilo o análogos del mismo para el tratamiento y/o prevención de la disfunción endotelial.
CR9755A (es) Derivados de 1-h-pirrol sustituidos con 1-heterocíclilsulfonilo, 2aminoetilo, 5-(hetero-) arilo como inhibidores de la secreción de ácido
MX2017010195A (es) Sal de un compuesto de pirimido [6,1-a]isoquinolin-4-ona.
IT1392456B1 (it) Processo per la sintesi di di- o oligosaccaridi l-fucosilati e loro nuovi intermedi 2,3,4-tribenzil-fucosil-derivati.
SMP201000002B (it) Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile
AR076478A1 (es) Proceso para la preparacion de [4-(2-cloro-4-metoxi-5-metilfenil)-5-metil-tiazolo-2-il]-[2-ciclopropil-1-(3-fluoro-4-metilfenil)-etil]-amina
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
CL2010001588A1 (es) Proceso para preparar nodulos que comprenden al polimorfo i del inhibidor de protrombina metanosulfonato de etexilato de dabigatran; proceso para preparar una suspension que comprende metanosulfonato de etexilato de dabigatran utilizada en la preparacion de los nodulos.
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
AR060065A1 (es) Formas cristalinas de un compuesto
DK2035432T3 (da) 2-(substitueret amino)-benzothiazolsulfonamid-HIV-proteaseinhibitorer
DOP2006000234A (es) Inhibidores de cinasa
CU20100252A7 (es) Derivados de dibenzotiazepina
BRPI0715051A2 (pt) Processo e intermediários para a síntese de derivados de 2-(quinolin-5il)-4,5 dissubstituído-azol
DOP2011000154A (es) 3-aminociclopentancarboxamidas
IT1392392B1 (it) Processo per la purificazione di una corrente acquosa proveniente dalla reazione di fischer-tropsch
PY1976957A (es) Formas cristalinas de un compuesto de quinazolina y sus sales de clorhidrato.-
CO6761339A2 (es) Derivados heterocíclicos diazeniodiolato de amina promaria
AR054394A1 (es) Derivados de 2- (1h-indolilsulfanil)-aril amina
CY1118305T1 (el) Πολυμορφικη μορφη της ν-[4-(τριφθορομεθυλο)βενζυλο]-4-μεθοξυβουτυραμιδης
BR112017021336A2 (pt) método para produzir acilsulfamoilbenzamidas.
EP4314426C0 (de) Wc-desodorierungsvorrichtung mit sprühkopf
EA200901229A1 (ru) Новый способ получения левоцетиризина и его промежуточных соединений